Global Smart Inhaler Market (2021 to 2030)

Dublin, May 03, 2022 (GLOBE NEWSWIRE) — The “Smart Inhalers Market by Product, Indication and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030” report has been added to from offer.

According to Verified Market Research, Global Smart Inhaler Market was valued at USD 118 Million in 2020 and is projected to reach USD 1,113.57 Million by 2030, growing at a CAGR of 25.1% from 2021 to 2030.

Smart inhalers are devices used to deliver a variety of inhaled medications and can be connected to devices such as smartphones or any other digital device. Medications used in inhalers include anticholinergics, glucocorticoids, insulin, and beta-agonists for the treatment and prevention of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Smart inhalers have sensors that send feedback, reminders and regularly monitor an individual’s health. It also flags high pollution areas as well as high pollen threat.

Smart inhalers have been shown to increase adherence rates in patients with asthma and COPD. Moreover, smart inhalers also help to monitor the technique used to inhale the medicine efficiently compared to normal inhalers. Smart inhalers are of two types, namely metered dose inhalers and dry powder inhalers.

This market is mainly driven by the increase in the population suffering from asthma and COPD. Rising air pollution directly increases asthma and other respiratory cases, which, in turn, drives the demand for smart monitoring devices. According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019 and more than 80% of these deaths occurred in low- and middle-income countries. Thus, such high mortality and unmet medical demands can be reduced by increased initiatives and use of smart inhalers and provide an opportunity for investors to invest in these countries.

For example, in July 2020, Novartis International AG, a major player, received European Commission (EC) approval for Enerzair Breezhaler, the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the European Union. . It was developed in conjunction with Propeller Health’s app and sensor specifically designed for the Breezhaler device. Thus, the launch of such products and collaborations among the major players in the market are further boosting the growth of the market.

Market players have invested in the development of various smart inhaler products that help in monitoring asthma and COPD, wherein the data acquired by the sensors of these smart inhalers is shared with the patient and healthcare professionals to track their inhaler use. The monitored data is then shared using Bluetooth technology with their mobile apps through an online platform and thereafter Electronic Health Records (EHRs) or Electronic Medical Records (EMRs) are maintained.

Smart inhalers are expected to increase patient adherence to traditional inhalers. Inadvertent non-adherence occurs when patients misunderstand instructions and forget or have physical problems such as poor coordination or poor eyesight, resulting in limited ability to take their medications. Smart inhalers, such as Adherium’s Hailie solution, are a cloud-based platform that captures medication usage data from Bluetooth-enabled sensors that wrap around patients’ inhalers and provide on-time feedback. real to patients through the Hailie app and to their physicians through the Hailie portal. . The increase in non-adherence is known to be a source of illness for patients as well as a financial burden for payers and prescribers. Thus, increasing adherence to smart inhalers should improve the treatment of patients with asthma and COPD.

However, as smart inhalers are connected wirelessly and keep a record of patient data, the risk of data leakage and misuse of data increases significantly. As the smart inhaler is a new device, its acceptance by patients as well as doctors is considerably low and hence is expected to restrain the market growth. Furthermore, the presence of a plethora of products in the pipeline and high market potential in untapped emerging economies are expected to provide attractive opportunities for market growth over the forecast period.

Key Players profiled in the report are Adherium Limited, Aptar Group Inc. (Cohero Health Inc.), AstraZeneca, Inc., Cognita Labs, Llc., GlaxoSmithKline Plc, Novartis AG, OPKO Health Inc., Philip Morris International Inc. ( Vectura Group Plc), ResMed Inc. (Propeller Health) and Teva Pharmaceutical Industries Ltd.

Key Benefits

  • This report provides an in-depth analysis of current and emerging market trends and dynamics in the global smart inhalers market to identify prevailing opportunities
  • This study presents the competitive landscape of the global market to predict the competitive environment across geographies
  • Comprehensive analysis of factors driving and restraining market growth is provided
  • Region and country analysis is provided to understand market trends and dynamics

Main topics covered:

Chapter 1 Introduction
1.1. Description of the report
1.2. Key market segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and templates

Chapter 2: Executive Summary
2.1. Cxo point of view

Chapter 3: Market Landscape
3.1. Market definition and scope
3.2. Main conclusions
3.2.1. Best Investment Pockets
3.2.2. Best Winning Strategies
3.3. Porter’s Five Forces Analysis
3.3.1. Bargaining power of suppliers
3.3.2. The threat of new entrants
3.3.3. The threat of substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining power among buyers
3.4. Market share analysis / Positioning of the best player
3.4.1. Market share analysis / Positioning of the best player 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Constraints
3.5.3. Opportunities
3.6. Covid-19 impact analysis

Chapter 4: Smart Inhalers Market, By Product
4.1. Market overview
4.1.1 Market Size and Forecast, by Product
4.2. Inhalers
4.2.1. Key Market Trends, Growth Drivers and Opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis, by country
4.2.4. Dry powder inhalers (Dpis) Market size and forecast
4.2.5. Metered dose inhalers (Mdis) Market size and forecast
4.3. Nebulizers
4.3.1. Key Market Trends, Growth Drivers and Opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis, by country

Chapter 5: Smart Inhalers Market, By Indication
5.1. Market overview
5.1.1 Market Size and Forecast, by Indication
5.2. Asthma
5.2.1. Market size and forecast, by region
5.2.2. Market share analysis, by country
5.3. COPD
5.3.1. Market size and forecast, by region
5.3.2. Market share analysis, by country

Chapter 6: Smart Inhalers Market, By End User
6.1. Market overview
6.1.1 Market Size and Forecast, by End User
6.2. Hospital pharmacies
6.2.1. Market size and forecast, by region
6.2.2. Market share analysis, by country
6.3. Retail pharmacies
6.3.1. Market size and forecast, by region
6.3.2. Market share analysis, by country

Chapter 7: Smart Inhalers Market, By Region

Chapter 8: Company Profiles
8.1. Adherium Limited
8.1.1. Company presentation
8.1.2. Key leaders
8.1.3. Company Overview
8.1.4. Operating business areas
8.1.5. Product portfolio
8.1.6. Company performance
8.1.7. Key strategic moves and developments
8.2. Aptar Group Inc. (Cohero Health Inc.)
8.2.1. Company presentation
8.2.2. Key leaders
8.2.3. Company Overview
8.2.4. Operating business areas
8.2.5. Product portfolio
8.2.6. Company performance
8.2.7. Key strategic moves and developments
8.3. Astrazeneca, Inc.
8.3.1. Company presentation
8.3.2. Key leaders
8.3.3. Company Overview
8.3.4. Operating business areas
8.3.5. Product portfolio
8.3.6. Company performance
8.3.7. Key strategic moves and developments
8.4. Cognita Labs, LLC
8.4.1. Company presentation
8.4.2. Key leaders
8.4.3. Company Overview
8.4.4. Operating business areas
8.4.5. Product portfolio
8.4.6. Key strategic moves and developments
8.5. GlaxoSmithKline plc
8.5.1. Company presentation
8.5.2. Key leaders
8.5.3. Company Overview
8.5.4. Operating business areas
8.5.5. Product portfolio
8.5.6. Company performance
8.6. Novartis AG
8.6.1. Company presentation
8.6.2. Key leaders
8.6.3. Company Overview
8.6.4. Operating business areas
8.6.5. Product portfolio
8.6.6. Company performance
8.6.7. Key strategic moves and developments
8.7. Opko Health Inc.
8.7.1. Company presentation
8.7.2. Key leaders
8.7.3. Company Overview
8.7.4. Operating business areas
8.7.5. Product portfolio
8.7.6. Company performance
8.8. Philip Morris International Inc. (Vectura Group plc)
8.8.1. Company presentation
8.8.2. Key leaders
8.8.3. Company Overview
8.8.4. Operating business areas
8.8.5. Product portfolio
8.8.6. Company performance
8.8.7. Key strategic moves and developments
8.9. Resmed Inc. (Propeller Health)
8.9.1. Company presentation
8.9.2. Key leaders
8.9.3. Company Overview
8.9.4. Operating business areas
8.9.5. Product portfolio
8.9.6. Company performance
8.9.7. Key strategic moves and developments
8.10. Teva Pharmaceutical Industries Ltd.
8.10.1. Company presentation
8.10.2. Key leaders
8.10.3. Company Overview
8.10.4. Operating business areas
8.10.5. Product portfolio
8.10.6. Company performance
8.10.7. Key strategic moves and developments

For more information on this report, visit